Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MitoRx Therapeutics logo — Developing new treatments to restore healthy mitochondrial m...

MitoRx Therapeutics

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.

Founded 2021 United Kingdom Oxford, United Kingdom 19 employees Seed Total: $4.00M Biotechnology, Health and Wellness

General Information

Company Name MitoRx Therapeutics
Founded Year 2021
Location United Kingdom Oxford, United Kingdom
Employees 19
Industries Biotechnology, Health and Wellness
Funding Stage Seed
Business Model B2B, Platform
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with MitoRx Therapeutics. To contact MitoRx Therapeutics, visit mitorxtherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MitoRx Therapeutics compare?

A PDF of MitoRx Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MitoRx Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MitoRx Therapeutics

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company founded in 2016 with the mission to arrest the progression of degenerative diseases driven by mitochondrial dysfunction. Their focus lies on neuromuscular disease, metabolic disease, and neurodegenerative disease. The company, headquartered in the United Kingdom, aims to become the leading global developer of medicines in this field. Their latest milestone includes a significant achievement with a £4.00M Seed Round investment at 13 December 2023, which was led by notable investors such as Oxford Technology Management, UK Innovation & Science Seed Fund, The Fink Family Office, Science Angel Syndicate, Wren Capital LLP, and LongevityTech.fund. MitoRx Therapeutics' dedication to addressing critical health challenges through innovative biotechnology positions the company as a potential game-changer in the biopharmaceutical industry.

Business keywords: biotech, rare disease, neuromuscular disease, metabolic disease, neurodegenerative disease, mitochondrial dysfunction, drug discovery, mitochondrial disease, Duchenne, mitochondria, muscular dystrophy, pre-clinical stage, therapeutics, novel, first-in-class

Services & Products

development of obesity treatments
restoration of mitochondrial metabolism
therapy for insulin resistance

Target Customers

individuals with high-risk obesity patients with metabolic disorders healthcare providers focusing on obesity

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round £4.00M 6
Oxford Technology Management UK Innovation & Science Seed Fund The Fink Family Office
Oxford Technology Management, UK Innovation & Science Seed Fund +4
13 Dec 2023
Seed Round Undisclosed 4
Oxford Technology Management Wren Capital LLP LongevityTech.fund
Oxford Technology Management, Wren Capital LLP +2
25 Apr 2022
Funding Round Undisclosed -
01 Mar 2019

MitoRx Therapeutics Alternatives & Competitors

View All Alternatives
MitoRx Therapeutics vs
Nanna Therapeutics
Nanna Therapeutics United Kingdom

Disease-modifying Medicines

Grant
20 employees
AI, Biotechnology
MitoRx Therapeutics vs
Iambic
Iambic United States

Better technology for better medicines | Nasdaq: IAM

194 employees
AI, Biotechnology
MitoRx Therapeutics vs
NeuroSense Therapeutics
NeuroSense Therapeutics United States

Creatively and diligently moving fast towards an effective treatment for people with ALS.

31 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About MitoRx Therapeutics

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.
MitoRx Therapeutics was founded in 2021.
MitoRx Therapeutics is headquartered in Oxford, United Kingdom.
MitoRx Therapeutics operates in Biotechnology and Health and Wellness. Its work centres on biotech, rare disease, neuromuscular disease and metabolic disease. Its customers include individuals with high-risk obesity, patients with metabolic disorders and healthcare providers focusing on obesity.
MitoRx Therapeutics has a B2B and Platform business model. Its revenue comes from Licensing, Product Sales and Performance Based.
MitoRx Therapeutics has approximately 19 employees.
MitoRx Therapeutics has completed 3 funding rounds, raising a total of $4.00M. The latest funding stage is Seed.
MitoRx Therapeutics offers: development of obesity treatments, restoration of mitochondrial metabolism, therapy for insulin resistance.
Top alternatives and competitors to MitoRx Therapeutics include Nanna Therapeutics, Iambic, NeuroSense Therapeutics, Elixirgen Therapeutics, Inc., Astrocyte Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MitoRx Therapeutics and Nanna Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MitoRx Therapeutics, https://bouncewatch.com/company/mitorx-therapeutics, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout